These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


136 related items for PubMed ID: 26188109

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
    Eastell R, Dijk DJ, Small M, Greenwood A, Sharpe J, Yamada H, Yuba M, Tanimoto M, Deacon S.
    Osteoporos Int; 2016 Jan; 27(1):309-18. PubMed ID: 26446770
    [Abstract] [Full Text] [Related]

  • 4. Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.
    Tanaka M, Hashimoto Y, Sekiya N, Honda N, Deacon S, Yamamoto M.
    J Bone Miner Metab; 2014 Jul; 32(4):447-54. PubMed ID: 24114194
    [Abstract] [Full Text] [Related]

  • 5. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
    Tanaka M, Hashimoto Y, Hasegawa C, Deacon S, Eastell R.
    BMC Musculoskelet Disord; 2017 Jun 19; 18(1):267. PubMed ID: 28629344
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.
    Clemens JD, Herrick MV, Singer FR, Eyre DR.
    Clin Chem; 1997 Nov 19; 43(11):2058-63. PubMed ID: 9365389
    [Abstract] [Full Text] [Related]

  • 10. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K, Kamimura M, Hashidate H, Uchiyama S, Nakagawa H.
    J Orthop Sci; 2007 May 19; 12(3):219-26. PubMed ID: 17530373
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
    Lindström E, Rizoska B, Henderson I, Terelius Y, Jerling M, Edenius C, Grabowska U.
    J Transl Med; 2018 May 09; 16(1):125. PubMed ID: 29743078
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover.
    Srivastava AK, Libanati C, Hohmann O, Kriegman A, Baylink DJ.
    Calcif Tissue Int; 2004 Dec 09; 75(6):477-81. PubMed ID: 15365658
    [Abstract] [Full Text] [Related]

  • 20. Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys.
    Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R, Kawada N, Kunishige A, Hashimoto Y, Tanaka M, Sugitani M, Kawabata K.
    Bone; 2014 Aug 09; 65():1-8. PubMed ID: 24784023
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.